Trans Genic Inc. (JP:2342)
:2342
Want to see JP:2342 full AI Analyst Report?
2342 Stock Chart & Stats
¥254.00
-¥3.00(-1.68%)
At close: 4:00 PM EST
¥254.00
-¥3.00(-1.68%)
Day’s Range― - ―
52-Week Range¥150.00 - ¥487.00
Previous CloseN/A
Volume37.40K
Average Volume (3M)549.15K
Market Cap
¥4.77B
Enterprise Value¥5.22B
Total Cash (Recent Filing)¥2.30B
Total Debt (Recent Filing)¥2.85B
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding16,999,142
10 Day Avg. Volume1,508,680
30 Day Avg. Volume549,150
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.23
P/FCF Ratio-37.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Research Tools & ServicesTrans Genic’s focus on genetically engineered animal models and related services addresses persistent demand in drug discovery and preclinical research. This niche has high technical barriers, recurring service needs and long sales cycles, supporting durable revenue streams and customer stickiness over multiple quarters.
Moderate Leverage And Stable Equity BaseA moderate debt load and stable equity ratio provide financial flexibility to fund R&D and operations despite operating losses. This balance sheet profile reduces immediate refinancing pressure and supports continued investment in core capabilities while management works to restore profitability.
Improving Operating Cash GenerationA recent positive shift in operating cash flow and a favorable operating-cash-to-net-income ratio indicate improving cash conversion despite reported losses. If sustained, this trend can enable the company to narrow negative free cash flow, fund critical projects internally, and reduce reliance on external financing.
Bears Say
Declining Revenue And Negative MarginsDeclining top-line and negative EBIT reflect weakening commercial traction and margin pressure. A sharply lower gross margin suggests rising costs or pricing pressure, limiting ability to scale profitably and constraining long-term reinvestment into product and service development.
Persistent Negative Free Cash FlowOngoing negative free cash flow limits capacity to self-fund growth and forces reliance on external financing or equity dilution. Persistent FCF deficits increase liquidity risk and can constrain R&D and capital spending choices, pressuring strategic flexibility over the medium term.
Earnings Volatility And Negative ROESharp EPS decline and modest negative revenue growth alongside a negative ROE signal unstable profitability and poor capital returns. This volatility undermines investor confidence and raises the likelihood of future capital raises, which could be dilutive and hamper long-term shareholder value creation.
2342 FAQ
What was Trans Genic Inc.’s price range in the past 12 months?
Trans Genic Inc. lowest stock price was ¥150.00 and its highest was ¥487.00 in the past 12 months.
What is Trans Genic Inc.’s market cap?
Trans Genic Inc.’s market cap is ¥4.77B.
When is Trans Genic Inc.’s upcoming earnings report date?
Trans Genic Inc.’s upcoming earnings report date is May 13, 2026 which is in 19 days.
How were Trans Genic Inc.’s earnings last quarter?
Trans Genic Inc. released its earnings results on Feb 10, 2026. The company reported -¥0.09 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.09.
Is Trans Genic Inc. overvalued?
According to Wall Street analysts Trans Genic Inc.’s price is currently Overvalued.
Does Trans Genic Inc. pay dividends?
Trans Genic Inc. pays a Annually dividend of ¥3 which represents an annual dividend yield of N/A. See more information on Trans Genic Inc. dividends here
What is Trans Genic Inc.’s EPS estimate?
Trans Genic Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trans Genic Inc. have?
Trans Genic Inc. has 16,999,142 shares outstanding.
What happened to Trans Genic Inc.’s price movement after its last earnings report?
Trans Genic Inc. reported an EPS of -¥0.09 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.922%.
Which hedge fund is a major shareholder of Trans Genic Inc.?
Currently, no hedge funds are holding shares in JP:2342
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Trans Genic Inc.
Trans Genic Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services. It also offers drug efficiency and pharmacological test and safety studies; sugar chain analysis and synthesis services; advice and support services, including M&A, business revitalization, business succession services; and contract production services, such as genetically modified mice, antibodies, protein hypers, and expressing cells, as well as sells mouse-related products and mouse models, and research reagents. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.
Technical Analysis
CellSource Co., Ltd.
―
ReproCELL Inc.
―
PhoenixBio Co., Ltd.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―